Platelet-activating Factor Receptor (PAFR) Antagonist

Platelet-activating Factor Receptor (PAFR) Antagonists (31):

Cat. No.	Product Name	Effect	Purity

HY-N0784

Ginkgolide B	Antagonist	99.96%
Ginkgolide B (BN-52021), a terpene lactone, is a potent platelet activating factor antagonist. Ginkgolide B protects endothelial cells via the activation of PXR from injuries induced by xeno- and endobiotics. Ginkgolide B can pass through the brain-blood barrier. Ginkgolide B has anti-oxidant, anti-inflammatory, anti-tumor, and anti-apoptotic activity. Ginkgolide B has marked neuroprotective effects against ischemia-induced impairments.

HY-N2071

Cedrol	Antagonist	≥98.0%
Cedrol is a potent competitive inhibitor of cytochrome P-450(CYP) enzyme. Cedrol plays an anticancer role by inducing cell cycle arrest and Caspase-dependent apoptosis. Cedrol acts as a neutrophil agonist that can desensitize cells to subsequent stimulation of N-formyl peptides. Cedrol prevents neuropathic pain caused by chronic contractile injury by inhibiting oxidative stress and inflammation. In addition, Cedrol has antibacterial, hair loss prevention and anti-anxiety properties.

HY-N0784R

Ginkgolide B (Standard)	Antagonist
Ginkgolide B (Standard) is the analytical standard of Ginkgolide B. This product is intended for research and analytical applications. Ginkgolide B (BN-52021), a terpene lactone, is a potent platelet activating factor antagonist. Ginkgolide B protects endothelial cells via the activation of PXR from injuries induced by xeno- and endobiotics. Ginkgolide B can pass through the brain-blood barrier. Ginkgolide B has anti-oxidant, anti-inflammatory, anti-tumor, and anti-apoptotic activity. Ginkgolide B has marked neuroprotective effects against ischemia-induced impairments.

HY-N10663

Kadsurenone	Antagonist	≥99.0%

HY-N7343

Pregomisin	Antagonist	99.87%
Pregomisin is a natural compound isolated from the fruits of Schizandra chinensis Baill. Pregomisin showed PAF antagonistic activity and the IC₅₀ values were 48 μM.

HY-163101

CP-96021	Antagonist	98.04%
CP-96021 is a potent and orally available leukotriene D₄ (LTD₄ K_i=34 μM) / platelet activating factor (PAF K_i=37 μM) receptor antagonist. CP-96021 has antagonist capable of simultaneously targeting two different inflammatory mediators, LTD₄ and PAF. CP-96021 shows high specificity for α1, α2, β, dopamine-2, adenosine 1, 5-HT1, H1, muscarine, μ opioid, and GABA receptors, all expressing IC₅₀ values greater than 10 μM. CP-96021 can be used to study the pathogenesis of many inflammatory diseases such as asthma.

HY-N12995

α-Bulnesene	Antagonist
α-Bulnesene is a novel PAF receptor antagonist with the IC₅₀ of 17.62 μM. α-Bulnesene can be isolated from Pogostemon cablin. α-Bulnesene shows inhibitory effect on platelet-activating factor and arachidonic acid induced rabbit platelet aggregation.

HY-19126

CL-184005	Antagonist
CL-184005 is an antagonist for platelet-activating factor (PAF), that inhibits the PAF-induced platelet aggregation with IC₅₀ of 600 nM and 510 nM, in human and rabbit platelet-rich plasma. CL-184005 protects the rats from endotoxin-induced gastrointestinal damage and hypotension. CL-184005 exhibits potential attenuating Gram-negative bacterial sepsis.

HY-N3436

Kadsurin A	Antagonist
Kadsurin A is a new lignan can be isolated from Piper futokadsura. Kadsurin A is a platelet activating factor (PAF) receptor antagonist that weakly inhibits the binding of PAF to its receptor.

HY-132190

Hexanolamino PAF C-16	Antagonist
Hexanolamino PAF C-16 (1-O-hexadecyl-2-acetyl-sn-glycero-3-phospho (N,N,N trimethyl) hexanolamine) is a Platelet-activating Factor Receptor (PAFR) Modulator with partial agonist activity. Hexanolamino PAF C-16 induces platelet aggregation and macrophage production but fails to increase [Ca2+]i in platelets, suggesting that PAF receptors may interact with PAF receptors through Ca²⁺-dependent and -independent pathways. Related to platelet aggregation.

HY-121377

Epiyangambin	Antagonist
Epiyangambin is a competitive platelet activating factor receptor (PAF) antagonist that dose-dependently inhibits PAF-induced platelet aggregation. Epiyangambin also inhibits the growth of human colon cancer cells (SW480 cells).

HY-132210

rel-(2R,4R)-2,4-Bis(3,4,5-trimethoxyphenyl)-1,3-dioxolane	Antagonist
rel-(2R,4R)-2,4-Bis(3,4,5-trimethoxyphenyl)-1,3-dioxolane (compound 6) is a platelet-activating factor receptor (PAFR) antagonist with a K_i of 0.3 µM.

HY-116120

N-Acetyldesloratadine	Antagonist	99.93%
N-Acetyldesloratadine (SCH-37370) is a potent, orally active dual antagonist of platelet-activating factor (PAF) and histamine. N-Acetyldesloratadine inhibits PAF-induced aggregation of human platelets, with an IC₅₀ of 0.6 µM.

HY-153717

LAU-0901	Antagonist
LAU-0901, a PAF receptor antagonist, possesses highly neuroprotective activity. LAU-0901 inhibits apoptosis.

HY-W700638A

Benafentrine maleate	Antagonist
Benafentrine maleate is a platelet activating factor receptor (PAFR) antagonist and a PDE 4 inhibitor.

HY-106837

Israpafant	Antagonist
Israpafant (Y-24180) is a potent, selective and long-acting platelet activation factor (PAF) receptor antagonist with IC₅₀s of 0.84 nM and 3.84 nM against PAF-induced human and rabbit platelet aggregation, respectively. Israpafant stimulates both extracellular Ca²⁺ influx and intracellular Ca²⁺ release in prostate cancer cells. Israpafant suppresses the allergic cutaneous reactions including eosinophilia, cytokine production, edema and erythema in mice.

HY-N12707

Kadsurenin C	Antagonist
Kadsurenin C (compound 1) is a neolignan that can be isolated from the aerial part of Piper kadsura with anti-inflammation activity. Kadsurenin C exhibits significant PAF (Platelet Activating Factor) antagonistic activity with IC₅₀ value of 5.1 μM.

HY-101654

Rocepafant	Antagonist
Rocepafant (BN 50730) is a specific platelet activating factor (PAF) antagonist. Rocepafant can be used in rheumatoid arthritis and nervous system research.

HY-106833A

SDZ-62-434	Antagonist
SDZ-62-434 is a platelet-activating factor (PAF) antagonist. SDZ-62-434 has antiproliferative activity in human solid and haematological malignancies.

HY-123399

Ro 19-1400	Antagonist
Ro 19-1400 is a platelet-activating factor antagonist that directly inhibits immunoglobulin E-dependent mediator release.

Name
Email *

	Sorry, but the email address you supplied was invalid.